Treatment Regimens in Meibomian Gland Dysfunction
Dry Eye Syndromes
About this trial
This is an interventional treatment trial for Dry Eye Syndromes
Eligibility Criteria
Inclusion Criteria:
1. Adult patients aged 18 or older, of any sex and any race. 2. Clinical diagnosis of MGD, defined as:
- complaints of burning, stinging or dryness > 40 on scale of 0-100.
- thickened secretions or occlusion of > 4 of eight assessed glands of the central lower eyelid.
clinically evident redness of the eyelid margin > 1+ on a scale of 0-4. 4. Willing to comply with the protocol instructions. 5. Has read (or has had read to), understood, and signed an Informed Consent.
-
Exclusion Criteria:
1. Active ocular infection or ocular inflammatory disease. 2. Anterior basement membrane dystrophy or history of recurrent erosion syndrome.
3. History of severe / serious ocular pathology or other medical condition that could result in an inability to safely complete the study. 4. Ocular surgery, LipiFlow or iLux or IPL or MG duct probing within past 6 months.
5. Participation by the patient in any other investigational study within the past 30 days.
6. Unlikely to comply with protocol instructions for any reason (confusion, substance abuse, etc.).
The Principal Investigator or the Medical Monitor reserves the right to declare a patient ineligible based on medical evidence that indicates the patient is unsuitable for the study.
Sites / Locations
- joseph Tauber
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Xiidra
Systane
one drop BID for 9 months
One drop QID for 9 months